Shares of Diplomat Pharmacy Inc (NYSE:DPLO) have received a consensus recommendation of “Hold” from the fourteen brokerages that are currently covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and two have given a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $17.89.
A number of equities analysts recently commented on the stock. Bank of America Corporation lifted their target price on shares of Diplomat Pharmacy from $17.00 to $18.50 and gave the stock a “neutral” rating in a research report on Thursday, May 25th. BidaskClub cut shares of Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Cowen and Company lifted their target price on shares of Diplomat Pharmacy from $12.00 to $17.00 and gave the stock a “market perform” rating in a research report on Tuesday, May 9th. Needham & Company LLC assumed coverage on shares of Diplomat Pharmacy in a research report on Friday, July 21st. They issued a “buy” rating and a $19.75 target price on the stock. Finally, Zacks Investment Research cut shares of Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research report on Monday, July 17th.
Shares of Diplomat Pharmacy (DPLO) traded up 8.78% during mid-day trading on Friday, hitting $16.60. 1,473,233 shares of the company traded hands. The firm’s 50 day moving average price is $15.76 and its 200-day moving average price is $15.65. The stock has a market capitalization of $1.11 billion, a PE ratio of 66.14 and a beta of 0.66. Diplomat Pharmacy has a 1-year low of $12.25 and a 1-year high of $37.83.
Diplomat Pharmacy (NYSE:DPLO) last issued its earnings results on Monday, August 7th. The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.15 by $0.10. The company had revenue of $1.13 billion for the quarter, compared to analysts’ expectations of $1.14 billion. Diplomat Pharmacy had a net margin of 0.39% and a return on equity of 2.84%. The firm’s revenue was up 3.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.23 EPS. On average, equities research analysts forecast that Diplomat Pharmacy will post $0.66 EPS for the current year.
Large investors have recently made changes to their positions in the company. New York State Teachers Retirement System increased its stake in shares of Diplomat Pharmacy by 1.1% in the fourth quarter. New York State Teachers Retirement System now owns 37,102 shares of the company’s stock valued at $467,000 after buying an additional 400 shares during the period. Envestnet Asset Management Inc. increased its stake in Diplomat Pharmacy by 32.5% in the first quarter. Envestnet Asset Management Inc. now owns 11,485 shares of the company’s stock worth $183,000 after buying an additional 2,820 shares during the last quarter. Two Sigma Investments LP purchased a new position in shares of Diplomat Pharmacy during the fourth quarter valued at approximately $1,547,000. Russell Investments Group Ltd. purchased a new position in shares of Diplomat Pharmacy during the fourth quarter valued at approximately $2,730,000. Finally, Dimensional Fund Advisors LP increased its position in shares of Diplomat Pharmacy by 4.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 303,696 shares of the company’s stock valued at $3,827,000 after buying an additional 11,902 shares in the last quarter. 72.02% of the stock is currently owned by institutional investors and hedge funds.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc and related companies with our FREE daily email newsletter.